Nuwiq (Simoctocog Alfa)

Simoctocog alfa, the active ingredient in Nuwiq, is a coagulation factor VIII (coagulant) presented as a recombinant protein for intravenous use. It replaces deficient factor VIII in patients with hemophilia A, helping to control and prevent bleeding episodes. GNH USA supplies Nuwiq as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

GNH USA supplies Nuwiq as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Nuwiq is a recombinant factor VIII product that acts within the coagulation cascade to manage bleeding disorders. - Hemophilia A (moderate to severe): Provides factor VIII replacement to prevent and control bleeding episodes. - Surgical prophylaxis in hemophilia A patients: Maintains adequate factor VIII levels during operative procedures. - Acute bleeding episodes in hemophilia A: Restores factor VIII activity to achieve hemostasis. - Routine prophylaxis in hemophilia A: Reduces frequency of spontaneous spontaneous bleeding episodes. - Peri‑   -  

Nuwiq  

Common  

   g